Asthma News - October 24, 2024

Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff. Sign up to receive weekly-ish news emails.

Check out the most recent MDHHS asthma social media messages and share them with your networks.

Green Door Initiative (GDI) is Hiring: Program Manager for Workforce & Program Manager for the Air Quality Division

GDI is an internationally known non-profit organization in Detroit whose mission is to ensure that every person is environmentally literate, capable of practicing and promoting sustainability as a lifestyle. GDI’s work includes advocacy in the areas of climate justice, environmental health, access to safe drinking water, job training and civic engagement. Two openings for Program Managers!

American Lung Association Webinar: Respiratory Virus Immunizations for Adults with Chronic Medical Conditions ~ Oct. 30 @ 1 PM

Join this free informative discussion of prevention strategies, as well as vaccination recommendations and where to get them. This webinar is specifically tailored for adults living with chronic medical conditions, such as asthma, COPD, diabetes and heart disease.

Environmental Protection Agency: Volatile Organic Compounds’ Impact on Indoor Air Quality

Volatile organic compounds (VOCs) include some chemicals that may have short- and long-term adverse health effects following exposure. VOCs can be found in many common household cleaning products, cosmetics, paints, and more, and can trigger asthma. Gases emitted from these products have chemical concentrations that can be up to 10 times higher in indoor spaces than outdoors.

Asthma and hypertension: the role of airway inflammation

A new study suggests that neutrophilic airway inflammation (as evaluated by induced sputum) is strictly associated with hypertension. Asthmatics with hypertension were more frequently male, older, and with higher body max index (BMI) when compared to normotensive patients.

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype.

AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

Airsupra (albuterol/budesonide) demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations when used as an as-needed rescue medication compared to albuterol alone, meeting the trial’s primary endpoint (patients aged 12 years and older).